Breaking News

ZyVersa Engages George Clinical for Phase 2a Trial

George Clinical to manage Phase 2a clinical trial with Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing drugs for renal and inflammatory diseases, has selected George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin 1Q24.   George Clinical, a global CRO headquartered in Sydney, Australia, provides clinical trial services to pharmaceutical, medical device, and diagnostic customers ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters